Coral is founded by Harvard and MIT PhD’s focused on harnessing diversity to optimize the drug prediction process. Coral improves drug development and deployment by utilizing genomic data from patients to determine how they will respond to a drug before they get treated.
Early revenue stream will come from drug prediction:
Predict patients unlikely to respond to novel drugs for biotech partners
Recommend adjuvants + discover new targets
$3bn market size